BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Takeda and Zuellig Pharma partner to expand medicine access across Southeast Asia

November 19, 2026 | News

Zuellig Pharma will support the commercialisation and distribution of selected Takeda products in Malaysia, Indonesia and the Philippines



Japan-based Takeda and Singapore's Zuellig Pharma have announced a strategic regional collaboration to enhance sustainable patient access to innovative medicines and healthcare solutions across Malaysia, Indonesia and the Philippines.

Effective December 1, 2026, the collaboration will bring together selected products from Takeda's innovative portfolio with Zuellig Pharma's extensive regional network, commercial capabilities and deep local market expertise, to strengthen sustainable access to medicines and improve health outcomes across the region.

Building on the long-standing relationship between the two companies, the collaboration combines complementary capabilities to support patients, healthcare professionals and healthcare systems across the three countries, with Zuellig Pharma supporting the end-to-end commercialization as well as distribution of selected Takeda products in the markets.

Takeda remains committed to serving patients, healthcare professionals and communities across Malaysia, Indonesia and the Philippines through its continued direct management of key portfolios and its new strategic regional collaboration with Zuellig Pharma. Takeda will continue to directly manage its vaccines portfolio across all three countries. In Indonesia, its locally manufactured medicine through the PT Takeda Indonesia (PTTI) joint venture and plasma-derived therapies portfolio will also remain under Takeda’s direct management, supporting continued access and care for patients.